(Q38072091)

28 August 2017

1 reference

title

Flecainide acetate for the treatment of atrial and ventricular arrhythmias (English)

1 reference

28 August 2017

1 reference

ChEBI release 2020-05-28

Larissa Fabritz

4

0 references

Paulus Kirchhof

object named as

Paulus Kirchhof

series ordinal

6

0 references

Günter Breithardt

series ordinal

5

object named as

Günter Breithardt

1 reference

28 August 2017

1

Stavros Apostolakis

1 reference

28 August 2017

Michael Oeff

2

1 reference

PubMed ID

23294160

28 August 2017

Ulrich Tebbe

series ordinal

3

1 reference

PubMed ID

23294160

28 August 2017

language of work or name

English

0 references

publication date

7 January 2013

1 reference

Expert Opinion on Pharmacotherapy

28 August 2017

1 reference

28 August 2017

14

1 reference

28 August 2017

3

1 reference

28 August 2017

347-357

1 reference

Discovery and development of flecainide

28 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.759212

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.759212

Classification by type of ventricular arrhythmia predicts frequency of adverse cardiac events from flecainide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.759212

Efficacy of flecainide in the management of ventricular arrhythmias: comparative study with amiodarone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.759212

Hemodynamic effects of intravenous flecainide relative to the level of ventricular function in patients with coronary artery disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.759212

Long-term efficacy and safety of flecainide for supraventricular tachycardia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.759212

Acute pharmacologic conversion of atrial fibrillation and flutter: the role of flecainide, propafenone, and verapamil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.759212

Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.759212

Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.759212

Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.759212

2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.759212

CAST and beyond. Implications of the Cardiac Arrhythmia Suppression Trial. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.759212

2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.759212

Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.759212

Postrepolarization refractoriness versus conduction slowing caused by class I antiarrhythmic drugs: antiarrhythmic and proarrhythmic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.759212

Effects of CYP2D6 genotypes on age-related change of flecainide metabolism: involvement of CYP1A2-mediated metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.759212

21 January 2018

Drug therapy. Flecainide

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.759212

Pharmacology of cardiac potassium channels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.759212

Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.759212

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.759212

Usefulness of flecainide for prevention of paroxysmal atrial fibrillation and flutter. Danish-Norwegian Flecainide Multicenter Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.759212

Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. The Flecainide Multicenter Atrial Fibrillation Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.759212

A randomized comparison of amiodarone and class IC antiarrhythmic drugs to treat atrial fibrillation in patients paced for sinus node disease: the Prevention Investigation and Treatment: A Group for Observation and Research on Atrial arrhythmias (PI

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.759212

Short- and long-term efficacy and safety of flecainide acetate for supraventricular arrhythmias

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.759212

Long-term results of hybrid therapy in patients with atrial fibrillation who develop atrial flutter during flecainide infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.759212

Evaluation of flecainide acetate in the management of patients at high risk of sudden cardiac death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.759212

Inefficacy and proarrhythmic effects of flecainide and encainide for sustained ventricular tachycardia and ventricular fibrillation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.759212

Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.759212

Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.759212

Guidelines for the diagnosis and management of Catecholaminergic Polymorphic Ventricular Tachycardia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.759212

Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.759212

Management of atrial fibrillation: review of the evidence for the role of pharmacologic therapy, electrical cardioversion, and echocardiography

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.759212

Antiarrhythmic therapy and risk of death in patients with atrial fibrillation: a nationwide study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.759212

Systematic review and meta-analysis of the efficacy of cardioversion by vernakalant and comparators in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.759212

Reversion of recent-onset atrial fibrillation to sinus rhythm by intravenous flecainide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.759212

Flecainide versus ibutilide for immediate cardioversion of atrial fibrillation of recent onset.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.759212

Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.759212

10.1517/14656566.2013.759212

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference

PubMed ID

23294160